HOME >> MEDICINE >> NEWS
Fatigue a lasting problem after liver transplantation

A new study on fatigue experienced by patients after undergoing liver transplantation found that it is a major problem that does not tend to improve with the passage of time. Liver transplant patients experience physical fatigue and reduced activity rather than mental fatigue and reduced motivation.

The results of this study appear in the June 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/livertransplantation.

Although fatigue is common in end-stage liver disease and can even contribute to the need for a liver transplant, few studies have been conducted on fatigue after liver transplants take place. In the current study, researchers led by Rita van den Berg-Emons, Ph.D. of the Department of Rehabilitation Medicine at the Erasmus Medical Center in Rotterdam, The Netherlands, assessed 96 liver transplant patients who visited the hospital's outpatient clinic between February and June 2003. The patients were given a series of self-administered questionnaires: the Fatigue Severity Scale (FSS) measured fatigue severity; the Multidimensional Fatigue Inventory (MFI-20) measured the nature of fatigue; two additional questionnaires measured the patients' disability level and their health-related quality of life (HRQoL). In addition, the researchers assessed patients' age, gender, reason for having the transplant, time since the transplant took place, and the number of immunosuppressive agents they were taking.

The results showed that 66 percent of the patients were fatigued, 44 percent were severely fatigued, and there was no indication that fatigue lessened over time. "T
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
1-Jun-2006


Page: 1 2 3

Related medicine news :

1. Fatigue and breast cancer survivors
2. Benefits of trastuzumab are lasting, reducing both HER2 + breast cancer deaths and recurrence
3. New allergy vaccine provides long-lasting hay fever relief after just 6 weeks of shots
4. Maintenance therapies offer lasting heart health benefits
5. Procedure for irregular heartbeat gives long-lasting relief & improves quality of life
6. Significant number of emphysema patients would find lasting benefit from lung surgery
7. MabThera A unique approach providing lasting benefits for patients with rheumatoid arthritis
8. IBS study shows that targeted antibiotics lead to long-lasting improvement in symptoms
9. Neuroscientists identify how trauma triggers long-lasting memories in the brain
10. Cognitive therapy works as well as antidepressants, but with lasting effect after therapy ends
11. Drug for cluster headaches may cause heart problems

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fatigue lasting problem after liver transplantation

(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: